Literature DB >> 30272271

Long non-coding RNA CUDR promotes malignant phenotypes in pancreatic ductal adenocarcinoma via activating AKT and ERK signaling pathways.

Xing Liang1, Meiyan Qi2, Rui Wu3, Anan Liu1, Danlei Chen1, Liang Tang1, Jun Chen1, Xiangui Hu4, Wei Li5, Lixing Zhan2, Chenghao Shao1.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, with a marked potential for invasion and metastasis. Emerging evidence has suggested that dysregulation of long non-coding RNAs (lncRNAs) is associated with the development of multiple types of cancer. However, the function of lncRNAs in PDAC is poorly known. In the present study, a microarray assay was used to screen for differently expressed lncRNAs in PDAC and it was identified that cancer upregulated drug resistance (CUDR) was upregulated in PDAC. CUDR increased PDAC cell proliferation, migration and invasion, inhibited apoptosis, and promoted drug resistance; it also regulated the PDAC cell epithelial-mesenchymal transition. The CUDR-induced PDAC malignant phenotypes is via the protein kinase B and extracellular-signal-regulated kinase signaling pathways. Downregulation of CUDR may be a novel therapeutic strategy to prevent PDAC development and drug resistance in the future.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30272271     DOI: 10.3892/ijo.2018.4574

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  5 in total

1.  LncRNA THOR promotes endometrial cancer progression through the AKT and ERK signaling pathways.

Authors:  Han-Qiu Zhang; Tao Li; Cheng Li; Hong-Tao Hu; Si-Meng Zhu; Jia-Qi Lu; Xiao-Jun Chen; He-Feng Huang; Yan-Ting Wu
Journal:  Med Oncol       Date:  2022-09-29       Impact factor: 3.738

2.  Identification of novel hub genes and lncRNAs related to the prognosis and progression of pancreatic cancer by microarray and integrated bioinformatics analysis.

Authors:  Xing Liang; Junfeng Peng; Danlei Chen; Liang Tang; Anan Liu; Zhiping Fu; Ligang Shi; Keqi Wang; Chenghao Shao
Journal:  Gland Surg       Date:  2021-03

3.  LINC00671 suppresses cell proliferation and metastasis in pancreatic cancer by inhibiting AKT and ERK signaling pathway.

Authors:  Shibin Qu; Kunwei Niu; Jianlin Wang; Jimin Dai; Anutosh Ganguly; Chao Gao; Yuzi Tian; Zhibin Lin; Xisheng Yang; Xuan Zhang; Zhengcai Liu; Haimin Li
Journal:  Cancer Gene Ther       Date:  2020-08-15       Impact factor: 5.987

4.  Analysis of lncRNA-mRNA networks after MEK1/2 inhibition based on WGCNA in pancreatic ductal adenocarcinoma.

Authors:  Jing Qian; Jianxin Yang; Xianchen Liu; Zhiming Chen; Xiaodi Yan; Hongmei Gu; Qiang Xue; Xingqin Zhou; Ling Gai; Pengpeng Lu; Yu Shi; Ninghua Yao
Journal:  J Cell Physiol       Date:  2019-10-03       Impact factor: 6.384

5.  The lncRNA 'UCA1' modulates the response to chemotherapy of ovarian cancer through direct binding to miR-27a-5p and control of UBE2N levels.

Authors:  Anaïs Wambecke; Mohammad Ahmad; Pierre-Marie Morice; Bernard Lambert; Louis-Bastien Weiswald; Mégane Vernon; Nicolas Vigneron; Edwige Abeilard; Emilie Brotin; Martin Figeac; Pascal Gauduchon; Laurent Poulain; Christophe Denoyelle; Matthieu Meryet-Figuiere
Journal:  Mol Oncol       Date:  2021-07-13       Impact factor: 6.603

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.